Schizophrenia Research
Volume 77, Issue 2 , Pages 119-128 , 15 September 2005

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

  • Georges M. Gharabawi

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560, USA
    • Corresponding Author InformationCorresponding author. 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560-0200, USA. Tel.: +1 609 730 3277; fax: +1 609 730 3125.
    • ,
  • Cynthia A. Bossie

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560, USA
    • ,
  • Robert A. Lasser

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560, USA
    • ,
  • Ibrahim Turkoz

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560, USA
    • ,
  • Stephen Rodriguez

      Affiliations

    • Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560, USA
    • ,
  • Guy Chouinard

      Affiliations

    • McGill University Health Center and University of Montreal, Centre de Recherche Fernand Séguin, Hôpital Louis-H Lafontaine, Montreal, QC, Canada

Received 12 November 2004 ,Revised 8 March 2005 ,Accepted 14 March 2005.

References 

  1. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. J. Psychiatry. 1999;174:23–30
  2. Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. J. Clin. Psychiatry. 2004;65(Suppl. 9):9–15
  3. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am. J. Psychiatry. 1979;136:79–82
  4. Chouinard G, Ross-Chouinard A, Annable L, Jones B. Extrapyramidal Symptom Rating Scale. Can. J. Neurol. Sci. 1980;7:234
  5. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 1988;8:21S–26S
  6. Chouinard G, Lasser R, Bossie C, Zhu Y, Gharabawi G. Does a long-acting atypical antipsychotic offer a low risk of tardive dyskinesia in patients with schizophrenia?. Biol. Psychiatry. 2003;53:81S–82S
  7. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry. 2004;161:414–425
  8. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revised (DSM-IV-TR), 2000. American Psychiatric Association, Washington, DC, pp. 803–805.
  9. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry. 2000;61:16–21
  10. Guy WA. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: U.S. Department of Health Education and Welfare; 1976;p. 534–537
  11. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr. Bull. 1993;19:303–315
  12. Jeste DV, Glazer WM, Morgenstern H, Pultz JA, Yeung PP. Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. In: Poster Presented at the 38th Annual Meeting of the American College of Neuropsychopharmacology. Acapulco, Mexico, December 12–16. 1999;
  13. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc. 1999;47:716–719
  14. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am. J. Geriatr. Psychiatry. 1999;7:70–76
  15. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J. Psychiatry. 2000;157:1150–1155
  16. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J. Clin. Psychiatry. 2004;65(Suppl. 9):16–20
  17. Loonen AJ, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE. The schedule for the Aassessment of Drug-induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. Int. J. Neuropsychopharmacol. 2000;3:285–296
  18. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry. 1993;50:723–733
  19. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. (Letter.) Arch. Gen. Psychiatry. 1982;39:486–487
  20. Sethi KD. Movement disorders induced by dopamine blocking agents. Semin. Neurol. 2001;21:59–68
  21. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry. 1997;154:1248–1254

PII: S0920-9964(05)00118-0

doi: 10.1016/j.schres.2005.03.008

Schizophrenia Research
Volume 77, Issue 2 , Pages 119-128 , 15 September 2005

Article Tools

* Image Usage & Resolution